A superior hypogastric plexus block is a specialized interventional procedure that targets the superior hypogastric plexus — a retroperitoneal network of sympathetic nerve fibers situated anterior to the lower abdominal aorta and the L4-L5 and S1 vertebral bodies, at the bifurcation of the common iliac vessels. This plexus serves as the primary sympathetic relay station for nociceptive signals originating from the pelvic viscera, including the uterus, cervix, ovaries, fallopian tubes, bladder, prostate, seminal vesicles, rectum, and sigmoid colon. By delivering local anesthetic and corticosteroid — or, in appropriate oncologic cases, neurolytic agents — directly to this plexus, the procedure interrupts the transmission of visceral pelvic pain signals before they ascend the sympathetic chain to the spinal cord.
The clinical significance of the superior hypogastric plexus block is most pronounced in the management of pelvic cancer pain, a complex and often devastating symptom that affects a substantial proportion of patients with advanced malignancies of the cervix, uterus, prostate, bladder, rectum, and ovary. Pelvic cancer pain is frequently refractory to systemic opioid therapy and is compounded by the side effects of high-dose analgesics — nausea, constipation, sedation, and cognitive impairment — which further diminish an already compromised quality of life. Superior hypogastric plexus neurolysis has been shown in prospective trials and systematic reviews to provide superior pain control with reduced opioid requirements compared to systemic analgesic therapy alone in appropriately selected patients.
Beyond its oncologic applications, superior hypogastric plexus block with local anesthetic and corticosteroid serves as a valuable diagnostic and therapeutic tool in the management of chronic non-cancer pelvic pain syndromes, including endometriosis-related pain, interstitial cystitis/bladder pain syndrome, chronic prostatitis, and pelvic inflammatory disease — conditions that collectively affect a substantial proportion of the population and are among the most challenging pain conditions to treat effectively. At Interventional Pain Consultants, these blocks are performed by board-certified, fellowship-trained interventional pain specialists using state-of-the-art fluoroscopic imaging with multiplanar confirmation of needle tip position.
The patient is positioned prone on the fluoroscopy table with a pillow under the lower abdomen to reduce lumbar lordosis. After sterile preparation, the L4-L5 interspace is identified under anteroposterior fluoroscopic guidance, and the skin entry points are marked approximately 5-7 cm lateral to the midline on each side at the level of the L4-L5 interspace. Two 20- or 22-gauge, 5- to 7-inch spinal needles are advanced using a paramedian approach, directed medially and caudally toward the anterolateral surface of the L5 vertebral body. The needles are advanced until bony contact is made with the L5 vertebral body, then carefully walked off the anterolateral margin using a combination of anteroposterior, oblique, and lateral fluoroscopic views.
Once the needle tips are confirmed to be positioned at the anterolateral surface of the L5 vertebral body — immediately adjacent to the location of the superior hypogastric plexus — negative aspiration is performed to rule out intravascular or intrathecal needle placement. A small volume (2-3 mL) of non-ionic contrast medium is injected on each side under live fluoroscopy to confirm appropriate contrast spread pattern: the contrast should be seen spreading in a linear, retroperitoneal configuration along the anterior aspect of the L5 vertebral body, without vascular washout or intrathecal contrast pattern. Upon confirmation of safe and accurate needle positioning, the therapeutic injectate is delivered — typically 6-10 mL of 0.25% bupivacaine combined with 40 mg of triamcinolone acetonide per side, or for neurolysis, 8-10 mL of 50-100% ethanol or 6-10% phenol per side.
The procedure is performed on an outpatient basis and typically requires 20-30 minutes. The patient is positioned prone and may receive moderate sedation for comfort. During the injection, patients typically experience a sensation of pressure, warmth, or mild discomfort in the lower abdomen and pelvis. Following the procedure, patients are monitored for 30-45 minutes, with particular attention to postural vital signs given the expected splanchnic vasodilation and the potential for orthostatic hypotension — an expected effect of sympathetic blockade that typically resolves within 24-48 hours.
Patients may also experience transient diarrhea (from unopposed parasympathetic activity in the pelvic and lower gastrointestinal viscera) and a feeling of warmth in the lower extremities. These effects are expected, self-limited, and reflect the successful interruption of sympathetic efferent activity. Most patients are discharged home with a responsible adult driver and are advised to rest for the remainder of the day.
In the first 24-72 hours following the procedure, patients should maintain adequate oral hydration and change positions slowly to minimize orthostatic symptoms. The sensation of warmth and mild vasodilation in the lower extremities typically resolves over 2-3 days as the local anesthetic is metabolized and sympathetic tone gradually returns. Patients are advised to avoid driving, operating heavy machinery, making important decisions, or consuming alcohol for 24 hours following sedation. Most patients can resume normal activities within 2-3 days, with the exception of heavy lifting and strenuous exercise for one week.
For patients undergoing neurolysis, the therapeutic effect develops progressively over 48-96 hours as the neurolytic agent achieves complete axonal degeneration of the targeted sympathetic fibers. Maximal benefit is typically apparent within one week. For patients receiving anesthetic-steroid blocks, the corticosteroid reaches peak anti-inflammatory effect within 5-10 days. Patients are asked to maintain a pain diary during the first two weeks post-procedure to document the trajectory of their response, which guides decisions about repeat intervention or neuromodulation.
Superior hypogastric plexus blocks are most appropriate for patients whose pelvic pain has a clearly identifiable visceral component — pain that is described as deep, pressure-like, gnawing, or cramping, that is poorly localized to a specific pelvic structure, and that is often referred to the lower back, sacrum, or proximal thighs. The presence of somatic pain (sharp, well-localized, movement-related) suggests parietal peritoneal or musculoskeletal involvement and reduces the expected benefit from this procedure.
Contraindications include coagulopathy or therapeutic anticoagulation that cannot be safely interrupted, active systemic infection, known allergy to contrast media or injectate components, severe uncorrected hypovolemia, and anatomic distortion of the target area due to prior extensive retroperitoneal surgery or radiation therapy. Pre-procedural cross-sectional imaging (CT or MRI) is essential to evaluate the retroperitoneal anatomy and to detect any tumor involvement, lymphadenopathy, or vascular anomalies that might influence the technical approach. At Interventional Pain Consultants, we are committed to providing the highest standard of care for patients suffering from pelvic pain, employing a multidisciplinary approach that integrates interventional procedures with medical management, physical therapy, psychological support, and — when indicated — referral for surgical or radiation oncology consultation.
Reducing Pain. Improving Function. Enhancing Quality of Life.
We specialize in advanced pain management solutions, offering minimally invasive treatments to help patients live pain-free and improve their quality of life.